Analyst Research

Report Title Price
Provider: Sadif Analytics Prime
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Stock Traders Daily
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Endologix Inc Narrows FY 2013 Revenue Guidance To A Range In Line With Analysts' Estimates; Reaffirms FY 2013 EBITDA Guidance


Wednesday, 30 Oct 2013 04:05pm EDT 

Endologix Inc announced that for fiscal 2013, it expects revenue to be in the range of $131-$133 million, adjusted net loss per share, non-GAAP and defined below, that excludes the fair value adjustment to the Nellix contingent consideration liability and business development expenses, in the range of $(0.14) to $(0.18) per share, GAAP loss per share in the range of $(0.25) to $(0.29) per share, inclusive of $(0.11) per share of expenses related to the fair value adjustments to the Nellix contingent consideration and business development expenses and Adjusted EBITDA (non-GAAP and defined below) in the range of $(0.02) to $0.02 per share. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $133 million and EPS of $(0.18) for fiscal 2013. 

Company Quote

11.54
0.295 +2.62%
1:51pm EDT